HYDRAVOL IV- hydroxyethyl starch, sodium chloride injection, solution Vedco, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

HYDRAVOL IVTM

6% HYDROXYETHYL STARCH 130/0.4 IN 0.9% SODIUM CHLORIDE INJECTION

CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN

STERILE NONPYROGENIC SOLUTION

For Animal Use Only

DESCRIPTION

HYDRAVOL IVTM (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a sterile, non-pyrogenic solution indicated for the treatment and prophylaxis of hypovolemia. It is not a substitute for red blood cells or coagulation factors in plasma. May be administered via intravenous infusion using aseptic technique. It contains no antimicrobial agents.

Composition, Osmolarity, pH, Ionic Concentration HYDRAVOL IV™ 250 mL and 500 mL:

TABLE 1. PRODUCT INFORMATION/ COMPOSITION/OSMOLARITY/PH/IONIC CONCENTRATION				IONIC Concentration		
PRODUCT	Composition (g/L) HYDROXYET HYL STARCH 130/0.4	Composition (g/L) SODIUM CHLORIDE NaCl	Osmolarity (mOsmol/L) (calc)	pН	SODIUM	CHLORIDE
HYDRAVOL IVTM 250 mL	60	9.0	308	4.0-5.5	154	154
HYDRAVOL IVTM 500 mL	60	9.0	308	4.0-5.5	154	154

The container is free of PVC and phthalates

CLINICAL PHARMACOLOGY

HYDRAVOL IVTM contains hydroxyethyl starch in a colloidal solution which expands plasma volume when administered intravenously. Hydroxyethyl starch is a derivative of thin boiling waxy corn starch, which mainly consists of a glucose polymer (amylopectin). Substitution of hydroxyethyl groups on the glucose units of the polymer reduces the normal degradation of amylopectin by α-amylase in the body.

INDICATIONS

HYDRAVOL IVTM acts as plasma volume substitute for the treatment and prophylaxis of hypovolemia. It is not a substitute for red blood cells or coagulation factors in plasma.

CONTRAINDICATIONS

The use of HYDRAVOL IV™ is contraindicated in the following conditions:

- Known hypersensitivity to hydroxyethyl starch.
- Fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure.
- Renal failure with oliguria or anuria not related to hypovolemia.
- Patients receiving dialysis treatment.
- Severe hypernatremia or severe hyperchloremia.
- Intracranial bleeding.

WARNINGS

Anaphylactoid reactions (bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately, and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved.

Fluid status and rate of infusion should be assessed regularly during treatment, especially in patients with cardiac insufficiency or severe kidney dysfunction.

In cases of severe dehydration, a crystalloid solution should be given first. Generally, sufficient fluid should be administered in order to avoid dehydration.

Caution should be observed before administering HYDRAVOL IVTM to patients with severe liver disease or severe bleeding disorders. With the administration of certain hydroxyethyl starch solutions, disturbances of blood coagulation can occur depending on the dosage.

If administered by pressure infusion, air should be withdrawn or expelled from the bag through the administration port prior to infusion.

Do not introduce additives into this container.

ADVERSE REACTIONS

- Products containing hydroxyethyl starch may lead to Anaphylactoid/hypersensitivity reactions.
- Prolonged administrations of high dosages of Hydroxyethyl starch may cause prutirus (itching), hemodilution (resulting in dilution of blood components, e.g., coagulation factors and other plasma proteins, and in a decrease in hematocrit).
- If an adverse reaction does occur, discontinue the infusion and evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination, if deemed necessary.

PRECAUTIONS

- Do not administer unless solution is clear and seal is intact.
- This is a single dose unit. It contains no preservatives.
- Use entire contents when first opened.
- Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy, or whenever the patient's condition warrants such evaluation.

No interactions with other drugs or nutritional products are known. The safety and compatibility of additives have not been established.

DOSAGE AND ADMINISTRATIONS

- To be used as directed by a licensed veterinarian. HYDRAVOL IVTM is administered by intravenous infusion only. The daily dose and rate of infusion depend on the patient's blood loss, on the maintenance or restoration of hemodynamics and on the hemodilution (dilution effect).
- For use in one patient on one occasion only. Discard any unused portion. Care should be taken with administration technique to avoid administration site reactions and infection.
- HYDRAVOL IVTM can be administered repetitively over several days. The initial 10 to 20 mL should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions. See Warnings and Precautions.

ADULT DOSE

• As a general recommendation, the class of synthetic colloids are prescribed at doses up to 20 mL per kg of body weight per day in small animal patient In. In a 30 kg patient, this is a dose of 600 mL of HYDRAVOL IV™ (equivalent to 1.2 g hydroxyethyl starch and 3.1 mEq sodium per kg of body weight).

OVERDOSAGE

As with all plasma volume substitutes, overdosage can lead to overloading of the circulatory system (e.g., pulmonary edema). In this case, the infusion should be stopped immediately and, if necessary, a diuretic should be administered. See Warnings and Precautions.

DIRECTIONS FOR USE OF PLASTIC CONTAINER

To open

Tear overwrap at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

Preparation for administration

- 1. Suspend container from eyelet support.
- 2. Remove plastic protector from inlet/outlet port at bottom of container.
- 3. Attach administration set.

Warning: Do not introduce additives into this container.

STORAGE

Store at 15°C to 25°C (59°F to 77°F). Do not freeze.

HOW SUPPLIED

HYDRAVOL IV[™] (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) for intravenous infusion is supplied in the following primary container: Polyolefin bag with overwrap: 250 mL and 500 mL

NDC			
CODE	ITEM NUMBER	SIZE(mL)	PRODUCT NAME
50989-	VINV-HYDR-		HYDRAVOL IV™ (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium
888-15	250M	250 mL	Chloride Injection)
50989-	VINV-HYDR-		HYDRAVOL IV™ (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium
888-16	500M	500 mL	Chloride Injection)

Manufactured For: Vedco, Inc. 5503 Corporate Dr. St Joseph, MO 64507 USA

For a Copy of the Safety Data Sheet (SDS) or to report adverse reactions call Vedco, Inc. customer service $1\,(888)\,708-3326$

References

1. Silverstein D, Hopper K. Small Animal Critical Care Medicine. (2009)

Principal Display Panel

NDC 50989-888-15

HydraVol IVTM

6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection

FOR INTRAVENOUS INFUSION ONLY

250mL



250 mL

HydraVol IV™

6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection FOR INTRAVENOUS INFUSION ONLY

50 Each 100 mL contains:

Hydroxyethyl Starch 130/0.4 Sodium Chloride, USP

6 g 900 mg

In Water for Injection, USP

Electrolytes (mEq/L) Sodium 154, Chloride 154

pH 4.0 to 5.5

Calculated osmolarity 308 mOsmol/L

May contain Sodium Hydroxide or Hydrochloric Acid for pH adjustment.

If administered by pressure infusion, air should be withdrawn or expelled from

the bag through the medication / administration port prior to infusion.

Check for leakage by squeezing container firmly. 100

If any leakage, discard solution as sterility may be impaired.

Sterile. Nonpyrogenic. Single dose container.

Use immediately after opening. Discard unused portion.

Use only if solution is clear and container is undamaged.

Usual dosage: See package insert. 150

Store at 15° to 25°C (59° to 77°F). Do not freeze

PVC-Free Non-DEHP

Latex-Free

[Lot No. 000 000] 200

[Mft date. 08/2018]

[Exp date, 08/2020]

FOR ANIMAL USE ONLY

CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.



Manufactured for: 5503 Corporate Dr. St. Joseph, MO 64507

Custom er Service No. 1-888-708-3326

NDC 50989-888-16

HydraVol IV™

6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection

FOR INTRAVENOUS INFUSION ONLY

500mL

NDC 50989-888-16

100

400



500 mL

HydraVol IV™

6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection FOR INTRAVENOUS INFUSION ONLY

Each 100 mL contains:

Hydroxyethyl Starch 130/0.4

6 q

Sodium Chloride, USP

In Water for Injection, USP

..... 900 mg

Electrolytes (mEg/L) Sodium 154, Chloride 154

.....

Calculated osmolarity 308 mOsmol/L May contain Sodium Hydroxide or Hydrochloric Acid for pH

adjustment.

If administered by pressure infusion, air should be withdrawn or expelled from the bag through the medication / administration port prior to infusion.

Check for leakage by squeezing container firmly. 200

If any leakage, discard solution as sterility may be impaired.

Sterile. Nonpyrogenic. Single dose container.

Use immediately after opening. Discard unused portion.

Use only if solution is clear and container is undamaged.

Usual dosage: See package insert.

Store at 15° to 25°C (59° to 77°F). Do not freeze 300 **PVC-Free** Non-DEHP Latex-Free

[Lot No. 000 000]

[Mft date, 08/2018]

[Exp date. 08/2020]

FOR ANIMAL USE ONLY.

CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed



Manufactured for:



5503 Corporate Dr. St. Joseph, MO 64507

Customer Service No. 1-888-708-3326



HYDRAVOL IV

hydroxyethyl starch, sodium chloride injection, solution

Product Information

Route of Administration INTRAVENOUS

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HYDRO XYETHYL STARCH 130/0.4 (UNII: 1GVO236S58) (HYDRO XYETHYL STARCH 130/0.4 - UNII:1GVO236S58)	HYDROXYETHYL STARCH 130/0.4	6 g in 100 mL

Inactive Ingredients				
Ingredient Name	Strength			
WATER (UNII: 059QF0KO0R)				
SODIUM CHLORIDE (UNII: 451W47IQ8X)	900 mg in 100 mL			
SO DIUM HYDRO XIDE (UNII: 55X04QC32I)				
HYDRO CHLO RIC ACID (UNII: QTT17582CB)				

Packaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:50989-888-15	250 mL in 1 CONTAINER				
2	NDC:50989-888-16	500 mL in 1 CONTAINER				

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
UNAPPROVED DRUG OTHER		10/24/2018			

Labeler - Vedco, Inc. (021634266)

Registrant - Vedco, Inc. (021634266)

Revised: 12/2018 Vedco, Inc.